Fair Value Measurements (Details) - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2022
Samsung Bioepis
Liabilities:
Equity, ownership interest	49.90%		49.90%
Fair Value, Measurements Recurring
Assets:
Cash equivalents	$ 484.8	$ 610.7
Marketable equity securities	329.5	416.8
Derivative contracts	9.9	11.9
Plan assets for deferred compensation	39.0	37.5
Total	1,299.3	1,506.9
Liabilities:
Derivative contracts	27.3	31.6
Total	27.3	31.6
Fair Value, Measurements Recurring | Samsung Bioepis
Assets:
Other current assets, receivable	436.1	430.0
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring
Assets:
Cash equivalents	0.0	0.0
Marketable equity securities	329.5	416.8
Derivative contracts	0.0	0.0
Plan assets for deferred compensation	0.0	0.0
Total	329.5	416.8
Liabilities:
Derivative contracts	0.0	0.0
Total	0.0	0.0
Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis
Assets:
Other current assets, receivable	0.0	0.0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring
Assets:
Cash equivalents	484.8	610.7
Marketable equity securities	0.0	0.0
Derivative contracts	9.9	11.9
Plan assets for deferred compensation	39.0	37.5
Total	533.7	660.1
Liabilities:
Derivative contracts	27.3	31.6
Total	27.3	31.6
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis
Assets:
Other current assets, receivable	0.0	0.0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring
Assets:
Cash equivalents	0.0	0.0
Marketable equity securities	0.0	0.0
Derivative contracts	0.0	0.0
Plan assets for deferred compensation	0.0	0.0
Total	436.1	430.0
Liabilities:
Derivative contracts	0.0	0.0
Total	0.0	0.0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis
Assets:
Other current assets, receivable	$ 436.1	$ 430.0